低分子肝素治疗急性冠脉综合征的疗效及对外周血血细胞膜表面组织因子的影响

The efficacy of low molecular weight heparin in the treatment of acute coronary syndrome and its effect on the expression of cell surface tissue factor in peripheral blood

目的:探讨低分子肝素治疗急性冠脉综合征(ACS)的临床疗效以及对外周血血细胞膜表面组织因子的影响。方法:选取2015年1月至2016年9月承德医学院附属医院收治的80例ACS患者,按照随机数字表法将其分为观察组和对照组,每组40例。对照组采用常规治疗,观察组在对照组基础上采用低分子肝素钙治疗。比较两组临床疗效,观察治疗前、后外周血血细胞膜表面组织因子的表达及不良反应发生情况。结果:观察组治疗的总有效率为95.0%,明显高于对照组的77.5%,差异有统计学意义(P<0.05);与对照组相比,观察组治疗后外周血血细胞膜表面组织因子表达量明显降低,差异有统计学意义(P<0.05)。治疗期间两组患者均无严重不良反应发生。结论:低分子肝素治疗ACS具有较好的临床疗效及安全性,并且能抑制外周血血细胞膜表面组织因子的表达。

Objective.To study the clinical efficacy of low molecular weight heparin （LMWH） in the treat- ment of acute coronary syndrome （ACS） and its impact on the surface tissue factor of peripheral blood. Methods.80 ACS patients in our hospital from Jan 2015 to Sep 2016 were randomized into a control group （routine treatment） and an observation group （low molecular weight heparin）, with 40 cases per group. The clinical efficacy, the expression of surface tissue factor of peripheral blood cell pre- and post-treat- ment, and the adverse reactions during the treatment between the two groups were compared. Results. Compared to the control group, the total effective rate was significantly increased in the observation group （P〈0.05）, and the expression of peripheral blood cell surface tissue factor was obviously reduced at post- treatment in the observation group （P〈0.05）. No severe adverse reactions were noted in both groups. Conclusion. LMWH was effective and safe in the treatment of ACS, and it could inhibit the expression of the surface tissue factor of peripheral blood cell.